EFTA02581206

From: Jeffrey Epstein <[email protected]> Sent: Monday, February 24, 2014 9:23 PM To: Lesley Groff; Richard Kahn Subject: Re: Joe Thakuria give him 10k =div class=" mail uote">On Mon, Feb 24, 2014 at 5:21 PM, Lesley Groff <mailto > wrote: Sent from my =Phone Begin forwarded message: From: Joseph Thakuria <mailtha Date: =February 24 2014 4:08:44 PM EST To: Lesley Groff gt; Cc: Rich Kahn Subject: Re: Jeffr=y Epstein Really? Ok, done (pending approval through Partners/MGH =RB for my formal research study - about 5 weeks as we discussed). Can we get a little additional software budget for s=condary analyses? At least the $4K worth we would have gotten with an exom=? The rationale for this is so we don't have to completely rely only &=uot;black box" interpretation by Illumina. In my experience, Illumna&=39;s genome interpretation has been historically subpar. Not surprising si=ce they are primarily a next gen DNA sequencing instrumentation company - =ot really focused on analyses and genomic analyses software (though they d= have their own). It may be that we don't pull up a lot of extra info =ith additional software. But we won't know that one way or the other r=lying only on Ilumina's interpretation. Anyway, let me know. The budget/invoice is complete if =e all we are going after is one item: a rapid turnaround whole genome thro=gh Illumina for $11,400. I do think this is the best (highest quality) who=e genome you can get for the money but it is disappointing to me that thei= pricing has been essentially unchanged for years (the reason I expected t=is to be in the $5K range). I do think I can find a whole genome for aroun= $SK (perhaps through CGI) but again I'd question the quality of that =enome. (That was the research rationale for getting 1 from Illumina and 1 =rom CGI to compare results if the funding were available for this). EFTA_R1_01757292 EFTA02581206 Let me know if this needs any further clarification. Thanks again, Joe > wrote: On Mon, Feb 24, 2014 at 3:=6 PM, Lesley Groff Hi Joe&h=llip;below is Jeffrey's reply: <mailto let= start and do the full genome with rapid turn around. 11, 400 On Feb 24, 2014, at 3:38=PM, Joseph Thakuria cmailto > wrote: Hi Lesley and Rich, Lesley, can you forward the following info to Jeffrey? So when I sent the initial invoice I didn't have =he actual whole genome costs through Illumina which are $9500 for a normal=turn around time and $11,400 for "rapid turn around time". The r=pid turn around time isn't necessary in Jeffrey's case. And, in my=opinion, if the budget is only $5000, I think the most bang for his buck (=nd this is what I would do for myself with only $5000 to spend) is to get =n exome done. I should be able to get this through Ambry and through the s=me research protocol we'll be suing for the YPO study participants for=$1000. I would then use the remainder to purchase genome analyses tools (t=ere won't be enough for any servers) to perform secondary analyses on =he exome. The exome only represents around 1.5% of the genome b=t this is the medically most important part of the genome (at least given =ur current knowledge) and represents all the coding regions in all our 20,=00+ genes. If this sounds good to Jeffrey, I'll produce a Tina= budget before the end of the week that specifies which of the tools we L=;11 be able to get with the remaining $4000. (I need to finish pricing and=tallying up features among the 6 I listed to determine which one(s) will g=t. This won't of course cover any cellular work or oth=r items in the full invoice but I would still recommend moving at least so=e fibroblast cell lines aliquots from the PGP to our new study so we can w=rk on those when funding from other sources is available. I would also just throw out there for Jeffrey's con=ideration that the same ambitious protocol for a stripped down clinical ne=t generation DNA sequencing laboratory could be pursued with a similar bucket on the commercial side - and I've already been in discussion with o=hers about funding this effort. Having followed this space since 2005 I ca= say the timing is very good for this type of business right now. Again, i= hasn't even been more than a year that this technology has transition=d into clinical care. So if this is something Jeffrey would be interested =n pursuing as an investor with an equity stake, rather than as a philanthr=pic grant for academic research, that would be another route for going ahe=d with the full project that he may be interested in discussing further.</=iv> 2 EFTA_R1_01757293 EFTA02581207 Rich, I'll leave it to you on how you'd like to-handle the $5000 invoice. I could receive this as a lump sum and account f=r how it is spent. I would expect all of it to be used up before the end o= the summer. We can also arrange it so that as the various vendors (sequen=ing and software) provide invoices, your office pays them directly. Either=way is fine with me. I don't have a preference. Thanks and let me know if I can provide any clarificati=ns. Again, I'll follow up with an invoice capped at $5K before the end=of the week (assuming you agree with the above). Joe Thakuria <=iv class=" mail uote">On Fri, Feb 21, 2014 at 6:34 PM, Lesley Groff <mailto > wrote: Hello Joe. I have Jeffrey's accountant o= this email as well, Rich Kahn . Jeffrey has told Rich he would like to do=a $5000 genetic work up done for the time being. Could you coordinate with=Rich regarding payment/next steps? Thank you, Lesley Assistant to Jeffrey Epstein Sent from my iPhone *********** **** ***** *Milt ***** *Mt ********* ****•***•**• **Ai The inform=tion contained in this communication is confidential, may be attorney-c=ient privileged, may constitute inside information, and is intended only for the use of the a=dressee. It is the property of Jeffrey Epstein Unauthorized use, di=closure or copying of this communication or any part thereof is strictl= prohibited and may be unlawful. If you have received this communication in error, p=ease notify us immediately by return e-mail or by e-mail to [email protected], =nd destroy this communication and all copies thereof, including all attachm=nts. copyright -all rights reserved 3 EFTA_R1_01757294 EFTA02581208